For kidney transplant patients, immunosuppressive therapy must be reshaped, in particular, mycophenolate, azathioprine and calcineurin inhibitors must be suspended during the active phases of the disease [150]. Tocilizumab, on the other hand, may be effective in these patients, but randomized trials are needed [157].